Adicet to become public company via resTORbio merger

Cell therapy developer Adicet will merge with resTORbio to form a public company that will trade under Adicet’s name.

The combined company will develop Adicet Bio Inc.’s pipeline of allogeneic γδ T cell therapies, including ADI-001 for non-Hodgkin lymphoma. The therapy is a CAR-T cell therapy targeting CD20...